Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Rating) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 24,700 shares, an increase of 34.2% from the October 31st total of 18,400 shares. Based on an average trading volume of 90,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the company's shares are short sold.
Analysts Set New Price Targets
Several research firms recently commented on XLO. Raymond James dropped their price objective on Xilio Therapeutics from $31.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday, November 10th. Morgan Stanley decreased their price objective on Xilio Therapeutics from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 10th. Finally, Guggenheim decreased their target price on Xilio Therapeutics to $15.00 in a research note on Tuesday, November 15th.
Get Xilio Therapeutics alerts:Hedge Funds Weigh In On Xilio Therapeutics
Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in shares of Xilio Therapeutics by 47.7% in the first quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company's stock valued at $149,000 after purchasing an additional 6,791 shares during the last quarter. State Street Corp grew its position in Xilio Therapeutics by 58.5% in the first quarter. State Street Corp now owns 93,861 shares of the company's stock worth $664,000 after acquiring an additional 34,651 shares during the period. Bailard Inc. purchased a new position in Xilio Therapeutics in the second quarter worth approximately $107,000. Millennium Management LLC purchased a new position in Xilio Therapeutics in the second quarter worth approximately $146,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Xilio Therapeutics during the second quarter worth $220,000. Hedge funds and other institutional investors own 64.66% of the company's stock.
Xilio Therapeutics Trading Down 8.1 %
XLO opened at $2.50 on Wednesday. The firm has a market cap of $68.68 million and a price-to-earnings ratio of -0.74. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.04. Xilio Therapeutics has a 12 month low of $2.01 and a 12 month high of $20.59. The stock has a fifty day moving average price of $2.54 and a 200-day moving average price of $2.66.Xilio Therapeutics (NASDAQ:XLO – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. As a group, equities research analysts anticipate that Xilio Therapeutics will post -3.19 earnings per share for the current fiscal year.
About Xilio Therapeutics
(Get Rating)
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
- Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
喜力治療公司(納斯達克代碼:XLO-GET評級)11月份空頭股數業務大幅增長。截至11月15日,空頭股數共有24,700股,比10月31日的18,400股增加了34.2%。以90,900股的平均成交量計算,目前天數與回補比率為0.3天。目前,該公司0.3%的股票被賣空。
分析師設定新的價格目標
幾家研究公司最近對XLO發表了評論。Raymond James在11月10日星期四的一份研究報告中將Xilio治療公司的目標價從31.00美元下調至13.00美元,並對該股設定了“跑贏大盤”的評級。8月10日,星期三,摩根士丹利在一份研究報告中將喜力治療的目標價從32.00美元下調至20.00美元,並對該股設定了“增持”評級。最後,古根海姆在11月15日星期二的一份研究報告中將他們對希利奧治療公司的目標價下調至15.00美元。
到達喜力治療公司警報:對衝基金入股希利奧治療公司
對衝基金最近買賣了該公司的股票。紐約梅隆銀行(Bank Of New York Mellon Corp)第一季度增持Xilio Treeutics股票47.7%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有21,029股該公司股票,價值149,000美元,此前該公司在上一季度又購買了6,791股。道富集團在第一季度將其在希利奧治療公司的頭寸增加了58.5%。道富銀行在此期間增持了34,651股,目前持有93,861股該公司股票,價值664,000美元。Bailard Inc.在第二季度購買了Xilio治療公司的一個新頭寸,價值約10.7萬美元。千禧管理公司在第二季度購買了希利奧治療公司的一個新頭寸,價值約14.6萬美元。最後,復興技術有限責任公司在第二季度購買了價值22萬美元的西利奧治療公司的新股票頭寸。對衝基金和其他機構投資者持有該公司64.66%的股票。
西利奧治療公司股價下跌8.1%
XLO週三開盤報2.50美元。該公司市值為6868萬美元,市盈率為-0.74倍。該公司的流動比率為8.45,速動比率為8.45,債務權益比率為0.04。希利奧治療的12個月低點為2.01美元,12個月高位為20.59美元。該股的50日移動均價為2.54美元,200日移動均價為2.66美元。喜力治療(納斯達克:XLO-GET評級)上一次公佈季度收益是在11月9日星期三。該公司公佈了本季度每股收益(0.72美元),比普遍預期的(0.89美元)高出0.17美元。作為一個整體,股票研究分析師預計,希利奧治療公司本財年的每股收益將達到3.19美元。
關於希利奧治療公司
(獲取評級)
Xilio Treateutics,Inc.是一家臨牀階段的生物技術公司,開發免疫療法來改善癌症患者的免疫系統。其檢查點抑制計劃包括XTX101,這是一種臨牀分期、腫瘤選擇性的抗CTLA-4單抗,正處於實體瘤患者的1/2期臨牀試驗中。
專題報道
- 免費獲取StockNews.com關於希利奧治療公司(XLO)的研究報告
- 哪些股票是黑色星期五,網絡星期一的贏家和輸家?
- 看好Organigram的三個原因
- 機遇來了!Hibbett,Inc.業績強勁,股價持平
- 為什麼投資者正在吞併餐飲品牌國際公司
- 通過標準化,Zoom Video繼續發揮作用
接受《喜力治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Xilio Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧